Compare Freshworks Inc (FRSH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Inovio Pharmaceuticals Inc — how do they compare? Freshworks Inc trades at $10.61 (market cap $2.93B), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: Freshworks Inc is far larger — about 30.4× Inovio Pharmaceuticals Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | INO | |
|---|---|---|
Market Cap | $2.93B | $96.26M |
Sector | Technology | Health |
52-Week High | $14.77 | $2.87 |
52-Week Low | $6.88 | $1.05 |
Enterprise Value | $2.19B | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.88, up 3.92% with a bullish technical signal and strong revenue growth from $720M in 2024 to $839M in 2025. The company achieved profitability in 2025 with net income of $184M, reversing prior losses. Recent news highlights AI product launches and a key partnership with Vanquis, while analyst consensus is split evenly between Buy and Hold ratings.
The outlook is positive with accelerating revenue and a path to sustained profitability, though high EV/EBITDA of 51.08 suggests premium valuation. Risks include execution on AI initiatives and competitive pressure in SaaS. Wall Street sees 26-38% upside potential based on price targets, making FRSH an attractive growth story if margins expand as projected.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
